Evolution of New Lesions and its Temporal Patterns in Patients with Clinically Isolated Syndrome Treated with Subcutaneous Interferon Beta-1a

2017 ◽  
Author(s):  
Hugo Vrenken
Keyword(s):  
Interferon Beta ◽  
Temporal Patterns ◽  
Clinically Isolated Syndrome

scholarly journals The Efficacy of Interferon Beta in Delaying Conversion to Clinically Definite Multiple Sclerosis

2010 ◽  
Vol 12 (1) ◽  
pp. 42-50 ◽  
Author(s):  
Marcelo Kremenchutzky ◽  
R. Philip Kinkel
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Interferon Beta ◽  
White Matter Lesions ◽  
Clinically Isolated Syndrome ◽  
Resonance Imaging ◽  
Phase 3 ◽  
Definite Multiple Sclerosis ◽  
Clinically Definite Multiple Sclerosis ◽  
Post Hoc

More than half of patients with a clinically isolated syndrome (CIS) develop clinically definite multiple sclerosis (CDMS). Patients at high risk for CDMS often present with asymptomatic lesions characteristic of CDMS on magnetic resonance imaging scans, although an absence of asymptomatic lesions is not atypical. Phase 3 studies of interferon beta in patients with a CIS suggest that this treatment can delay conversion to CDMS and reduce the risk of new asymptomatic white matter lesions. We reviewed phase 3 studies (CHAMPS, BENEFIT, and ETOMS) and post hoc analyses assessing the efficacy of interferon beta in delaying CDMS in patients with a CIS. The evidence supports early initiation of treatment.

Benefit 11: Long-term follow-up study of patients with clinically isolated syndrome treated with interferon beta-1b

2013 ◽  
Vol 333 ◽  
pp. e383
Author(s):  
L. Kappos ◽  
G. Edan ◽  
M. Freedman ◽  
X. Montalbán ◽  
D. Miller ◽  
...  
Keyword(s):  
Interferon Beta ◽  
Clinically Isolated Syndrome ◽  
Follow Up Study ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document